Published in Biomed Microdevices on April 01, 2012
Isolation and characterization of circulating tumor cells in prostate cancer. Front Oncol (2012) 0.98
Microfluidic transport in microdevices for rare cell capture. Electrophoresis (2012) 0.91
Enrichment of prostate cancer cells from blood cells with a hybrid dielectrophoresis and immunocapture microfluidic system. Biomed Microdevices (2013) 0.86
Characterization of microfluidic shear-dependent epithelial cell adhesion molecule immunocapture and enrichment of pancreatic cancer cells from blood cells with dielectrophoresis. Biomicrofluidics (2014) 0.86
Isolation of breast cancer and gastric cancer circulating tumor cells by use of an anti HER2-based microfluidic device. Lab Chip (2013) 0.84
Characterization of a hybrid dielectrophoresis and immunocapture microfluidic system for cancer cell capture. Electrophoresis (2013) 0.82
Generation of tissue constructs for cardiovascular regenerative medicine: from cell procurement to scaffold design. Biotechnol Adv (2012) 0.82
Parametric control of collision rates and capture rates in geometrically enhanced differential immunocapture (GEDI) microfluidic devices for rare cell capture. Biomed Microdevices (2014) 0.80
Tissue factor-expressing tumor cells can bind to immobilized recombinant tissue factor pathway inhibitor under static and shear conditions in vitro. PLoS One (2015) 0.75
Circulating tumor cells in prostate cancer: Precision diagnosis and therapy. Oncol Lett (2017) 0.75
Isolation of rare circulating tumour cells in cancer patients by microchip technology. Nature (2007) 19.33
Tumor cells circulate in the peripheral blood of all major carcinomas but not in healthy subjects or patients with nonmalignant diseases. Clin Cancer Res (2004) 14.53
Circulating tumor cells predict survival benefit from treatment in metastatic castration-resistant prostate cancer. Clin Cancer Res (2008) 14.37
Relationship of circulating tumor cells to tumor response, progression-free survival, and overall survival in patients with metastatic colorectal cancer. J Clin Oncol (2008) 8.72
Isolation of circulating tumor cells using a microvortex-generating herringbone-chip. Proc Natl Acad Sci U S A (2010) 7.77
Circulating tumour cells as prognostic markers in progressive, castration-resistant prostate cancer: a reanalysis of IMMC38 trial data. Lancet Oncol (2009) 5.45
Circulating tumor cell number and prognosis in progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 5.36
Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res (1997) 4.05
A rare-cell detector for cancer. Proc Natl Acad Sci U S A (2004) 3.95
Isolation and characterization of circulating tumor cells from patients with localized and metastatic prostate cancer. Sci Transl Med (2010) 3.90
Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. Cancer Res (1999) 3.58
Circulating tumor cell analysis in patients with progressive castration-resistant prostate cancer. Clin Cancer Res (2007) 3.53
Circulating tumour cell (CTC) counts as intermediate end points in castration-resistant prostate cancer (CRPC): a single-centre experience. Ann Oncol (2008) 3.44
The emerging role of EpCAM in cancer and stem cell signaling. Cancer Res (2009) 3.25
Upregulation of prostate-specific membrane antigen after androgen-deprivation therapy. Urology (1996) 2.77
Effect of flow and surface conditions on human lymphocyte isolation using microfluidic chambers. Langmuir (2004) 2.76
Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res (1997) 2.72
Design and construction of a linear shear stress flow chamber. Ann Biomed Eng (1993) 2.57
Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab Chip (2009) 2.56
Prostate-specific membrane antigen is produced in tumor-associated neovasculature. Clin Cancer Res (1999) 2.55
Circulating tumor cells as biomarkers in prostate cancer. Clin Cancer Res (2011) 2.17
Circulating tumor cells predict survival in patients with metastatic prostate cancer. Urology (2005) 2.15
Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res (2003) 2.11
Expression of the prostate-specific membrane antigen. Cancer Res (1994) 2.06
Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases. Urology (1998) 2.04
Circulating tumor cells: a window into cancer biology and metastasis. Curr Opin Genet Dev (2010) 2.03
Circulating tumour cells in cancer patients: challenges and perspectives. Trends Mol Med (2010) 2.02
All circulating EpCAM+CK+CD45- objects predict overall survival in castration-resistant prostate cancer. Ann Oncol (2010) 1.97
Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. Hum Pathol (2007) 1.95
Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. Anticancer Res (1988) 1.91
In vitro characterization of radiolabeled monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen. Cancer Res (2000) 1.91
Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res (2008) 1.77
Rare Cell Capture in Microfluidic Devices. Chem Eng Sci (2011) 1.68
Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen. Cancer (1998) 1.61
Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J (2006) 1.55
Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase. Proc Natl Acad Sci U S A (2005) 1.49
Expression of prostate-specific membrane antigen in normal, benign, and malignant prostate tissues. Urol Oncol (2011) 1.45
Detection and characterization of the prostate-specific membrane antigen (PSMA) in tissue extracts and body fluids. Int J Cancer (1995) 1.43
Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. Cancer Res (1994) 1.34
Is prostate-specific membrane antigen a multifunctional protein? Am J Physiol Cell Physiol (2005) 1.31
Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol (2009) 1.31
High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. Prostate (2010) 1.28
Targeted systemic therapy of prostate cancer with a monoclonal antibody to prostate-specific membrane antigen. Semin Oncol (2003) 1.24
A dual-monoclonal sandwich assay for prostate-specific membrane antigen: levels in tissues, seminal fluid and urine. Prostate (2000) 1.21
Circulating tumour cells lacking cytokeratin in breast cancer: the importance of being mesenchymal. J Cell Mol Med (2011) 1.17
Advancing personalized cancer therapy by detection and characterization of circulating carcinoma cells. Ann N Y Acad Sci (2010) 1.15
Enrichment using antibody-coated microfluidic chambers in shear flow: model mixtures of human lymphocytes. Biotechnol Bioeng (2005) 1.13
Expression of the gastrin-releasing peptide receptor, the prostate stem cell antigen and the prostate-specific membrane antigen in lymph node and bone metastases of prostate cancer. Prostate (2009) 1.06
Effects of EpCAM overexpression on human breast cancer cell lines. BMC Cancer (2011) 1.00
Circulating tumor cells in metastatic inflammatory breast cancer. Ann Oncol (2009) 0.93
Immunohistochemical detection of carcinoma in radical prostatectomy specimens following hormone therapy. Pathol Int (2008) 0.84
Programmable modification of cell adhesion and zeta potential in silica microchips. Lab Chip (2003) 0.84
Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. Sci Transl Med (2012) 5.92
Mesenchymal stem cell-mediated functional tooth regeneration in swine. PLoS One (2006) 3.91
Microfluidic scaffolds for tissue engineering. Nat Mater (2007) 3.12
89Zr-DFO-J591 for immunoPET of prostate-specific membrane antigen expression in vivo. J Nucl Med (2010) 2.82
Androgen receptor signaling in circulating tumor cells as a marker of hormonally responsive prostate cancer. Cancer Discov (2012) 2.76
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer. Cancer Res (2011) 2.69
Capture of circulating tumor cells from whole blood of prostate cancer patients using geometrically enhanced differential immunocapture (GEDI) and a prostate-specific antibody. Lab Chip (2009) 2.56
H3K9 methylation is a barrier during somatic cell reprogramming into iPSCs. Nat Genet (2012) 2.47
Phase I trial of yttrium-90-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for androgen-independent prostate cancer. J Clin Oncol (2004) 2.27
Vascular targeted therapy with anti-prostate-specific membrane antigen monoclonal antibody J591 in advanced solid tumors. J Clin Oncol (2007) 1.95
The hidden treasure in apical papilla: the potential role in pulp/dentin regeneration and bioroot engineering. J Endod (2008) 1.95
Prevention of cartilage degeneration in a rat model of osteoarthritis by intraarticular treatment with recombinant lubricin. Arthritis Rheum (2009) 1.94
Noninvasive measurement of androgen receptor signaling with a positron-emitting radiopharmaceutical that targets prostate-specific membrane antigen. Proc Natl Acad Sci U S A (2011) 1.87
Functional characterization of circulating tumor cells with a prostate-cancer-specific microfluidic device. PLoS One (2012) 1.86
Cellular microRNAs inhibit replication of the H1N1 influenza A virus in infected cells. J Virol (2010) 1.80
Rare Cell Capture in Microfluidic Devices. Chem Eng Sci (2011) 1.68
A microfluidic biomaterial. J Am Chem Soc (2005) 1.64
Radiolabeled monoclonal antibodies specific to the extracellular domain of prostate-specific membrane antigen: preclinical studies in nude mice bearing LNCaP human prostate tumor. J Nucl Med (2003) 1.61
A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell (2003) 1.60
Superparamagnetic iron oxide nanoparticle-aptamer bioconjugates for combined prostate cancer imaging and therapy. ChemMedChem (2008) 1.57
Anti-prostate-specific membrane antigen-based radioimmunotherapy for prostate cancer. Cancer (2010) 1.57
Phase II study of Lutetium-177-labeled anti-prostate-specific membrane antigen monoclonal antibody J591 for metastatic castration-resistant prostate cancer. Clin Cancer Res (2013) 1.51
Vitamin C modulates TET1 function during somatic cell reprogramming. Nat Genet (2013) 1.45
Lymphatic function is required prenatally for lung inflation at birth. J Exp Med (2014) 1.44
Mapping the depth dependence of shear properties in articular cartilage. J Biomech (2008) 1.41
Electrophoretic concentration of proteins at laser-patterned nanoporous membranes in microchips. Anal Chem (2004) 1.41
Targeted, activatable, in vivo fluorescence imaging of prostate-specific membrane antigen (PSMA) positive tumors using the quenched humanized J591 antibody-indocyanine green (ICG) conjugate. Bioconjug Chem (2011) 1.37
Binding and localization of recombinant lubricin to articular cartilage surfaces. J Orthop Res (2007) 1.34
Clinical use of monoclonal antibody HuJ591 therapy: targeting prostate specific membrane antigen. J Urol (2003) 1.31
Prostate-specific membrane antigen expression in the neovasculature of gastric and colorectal cancers. Hum Pathol (2009) 1.31
The imbalance of Th17/Th1/Tregs in patients with type 2 diabetes: relationship with metabolic factors and complications. J Mol Med (Berl) (2011) 1.30
First Cu(II) diamondoid net with 2-fold interpenetrating frameworks. The role of anions in the construction of the supramolecular arrays. Inorg Chem (2002) 1.29
Synthesis and in vitro testing of J591 antibody-dendrimer conjugates for targeted prostate cancer therapy. Bioconjug Chem (2004) 1.24
Continuous-flow particle separation by 3D Insulative dielectrophoresis using coherently shaped, dc-biased, ac electric fields. Anal Chem (2007) 1.24
Prostate-specific membrane antigen association with filamin A modulates its internalization and NAALADase activity. Cancer Res (2003) 1.22
Molecular mechanisms underlying the analgesic property of intrathecal dexmedetomidine and its neurotoxicity evaluation: an in vivo and in vitro experimental study. PLoS One (2013) 1.21
Rational optimization of reprogramming culture conditions for the generation of induced pluripotent stem cells with ultra-high efficiency and fast kinetics. Cell Res (2011) 1.19
Genome sequence of Stenotrophomonas maltophilia RR-10, isolated as an endophyte from rice root. J Bacteriol (2012) 1.18
Interactions between Siglec-7/9 receptors and ligands influence NK cell-dependent tumor immunosurveillance. J Clin Invest (2014) 1.16
Image-guided tissue engineering of anatomically shaped implants via MRI and micro-CT using injection molding. Tissue Eng Part A (2008) 1.16
Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen. J Nucl Med (2005) 1.14
Safety of homeopathic products. J R Soc Med (2002) 1.14
Sculpting organs: mechanical regulation of tissue development. Annu Rev Biomed Eng (2012) 1.11
⁸⁹Zr-huJ591 immuno-PET imaging in patients with advanced metastatic prostate cancer. Eur J Nucl Med Mol Imaging (2014) 1.10
Pharmacokinetics and biodistribution of 111In- and 177Lu-labeled J591 antibody specific for prostate-specific membrane antigen: prediction of 90Y-J591 radiation dosimetry based on 111In or 177Lu? J Nucl Med (2005) 1.10
Host epithelial geometry regulates breast cancer cell invasiveness. Proc Natl Acad Sci U S A (2012) 1.09
Radioimmunotherapy of prostate cancer using 90Y- and 177Lu-labeled J591 monoclonal antibodies: effect of multiple treatments on myelotoxicity. Clin Cancer Res (2005) 1.08
Modulation of lubricin biosynthesis and tissue surface properties following cartilage mechanical injury. Arthritis Rheum (2009) 1.08
Targeting the internal epitope of prostate-specific membrane antigen with 89Zr-7E11 immuno-PET. J Nucl Med (2011) 1.07
Real-time ultrasound elastography: its potential role in assessment of breast lesions. Ultrasound Med Biol (2008) 1.07
Genome sequence of the rice-pathogenic bacterium Acidovorax avenae subsp. avenae RS-1. J Bacteriol (2011) 1.07
The relationship between serum thyrotropin and components of metabolic syndrome. Endocr J (2010) 1.06
Radioimmunotherapy of Metastatic Prostate Cancer with 177Lu-DOTAhuJ591 Anti Prostate Specific Membrane Antigen Specific Monoclonal Antibody. Curr Radiopharm (2016) 1.02
Methods for photocrosslinking alginate hydrogel scaffolds with high cell viability. Tissue Eng Part C Methods (2010) 1.02
Stiffness of photocrosslinked RGD-alginate gels regulates adipose progenitor cell behavior. Biotechnol Bioeng (2011) 1.02
Microfluidic immunocapture of circulating pancreatic cells using parallel EpCAM and MUC1 capture: characterization, optimization and downstream analysis. Lab Chip (2014) 1.01
Microchip dialysis of proteins using in situ photopatterned nanoporous polymer membranes. Anal Chem (2004) 1.01
Automated dielectrophoretic characterization of Mycobacterium smegmatis. Anal Chem (2011) 1.01
Associations and impact factors between living arrangements and functional disability among older Chinese adults. PLoS One (2013) 1.01
Therapeutic benefits of human mesenchymal stem cells derived from bone marrow after global cerebral ischemia. Brain Res (2009) 0.99
Low-light-level optical interactions with rubidium vapor in a photonic band-gap fiber. Phys Rev Lett (2006) 0.99
Radioimmunotherapy of prostate cancer in human xenografts using monoclonal antibodies specific to prostate specific membrane antigen (PSMA): studies in nude mice. Prostate (2004) 0.98
Real-time PCR assays targeting formyltetrahydrofolate synthetase gene to enumerate acetogens in natural and engineered environments. Anaerobe (2009) 0.98
Isolation and characterization of circulating tumor cells in prostate cancer. Front Oncol (2012) 0.98
Synergistic cytotoxicity of irinotecan and cisplatin in dual-drug targeted polymeric nanoparticles. Nanomedicine (Lond) (2012) 0.97
Patterning, characterization, and chemical sensing applications of graphene nanoribbon arrays down to 5 nm using helium ion beam lithography. ACS Nano (2014) 0.97
Integration of layered chondrocyte-seeded alginate hydrogel scaffolds. Biomaterials (2007) 0.97
(6,6-Dimethyl-1-phenyl-6,7-di-hydro-5H-pyrrolizin-2-yl)(thio-phen-2-yl)methanone. Acta Crystallogr Sect E Struct Rep Online (2013) 0.96
Breast tumor size assessment: comparison of conventional ultrasound and contrast-enhanced ultrasound. Ultrasound Med Biol (2007) 0.96
Lx2-32c, a novel taxane and its antitumor activities in vitro and in vivo. Cancer Lett (2008) 0.95
Antibody-based therapeutics: focus on prostate cancer. Cancer Metastasis Rev (2005) 0.95
Synthesis of the optical isomers of a new anticholinergic drug, penehyclidine hydrochloride (8018). Bioorg Med Chem Lett (2005) 0.95
Saporin toxin-conjugated monoclonal antibody targeting prostate-specific membrane antigen has potent anticancer activity. Prostate (2010) 0.95
Prostate-specific membrane antigen as a potential novel vascular target for treatment of glioblastoma multiforme. Arch Pathol Lab Med (2011) 0.95
N-glycosylation and microtubule integrity are involved in apical targeting of prostate-specific membrane antigen: implications for immunotherapy. Mol Cancer Ther (2005) 0.94
Electrothermal flow effects in insulating (electrodeless) dielectrophoresis systems. Electrophoresis (2010) 0.93
High expression of prostate-specific membrane antigen in the tumor-associated neo-vasculature is associated with worse prognosis in squamous cell carcinoma of the oral cavity. Mod Pathol (2012) 0.93
Microfluidic transport in microdevices for rare cell capture. Electrophoresis (2012) 0.91
Microfluidic devices for terahertz spectroscopy of biomolecules. Opt Express (2008) 0.91
Public awareness of three major infectious diseases in rural Zhejiang province, China: a cross-sectional study. BMC Infect Dis (2013) 0.91
Microchip HPLC of peptides and proteins. Anal Chem (2005) 0.90
Accuracy of an automated breast volume ultrasound system for assessment of the pre-operative extent of pure ductal carcinoma in situ: comparison with a conventional handheld ultrasound examination. Ultrasound Med Biol (2013) 0.90
The utility of monoclonal antibodies in the imaging of prostate cancer. Semin Urol Oncol (2002) 0.89
Validation of a sensitive LC-MS assay for quantification of glyburide and its metabolite 4-transhydroxy glyburide in plasma and urine: an OPRU Network study. J Chromatogr B Analyt Technol Biomed Life Sci (2007) 0.88
Zeta potential and electroosmotic mobility in microfluidic devices fabricated from hydrophobic polymers: 2. Slip and interfacial water structure. Electrophoresis (2008) 0.88
Microfluidic isolation of cancer-cell-derived microvesicles from hetergeneous extracellular shed vesicle populations. Biomed Microdevices (2014) 0.88
The Rho kinase inhibitor Y-27632 facilitates the differentiation of bone marrow mesenchymal stem cells. J Mol Histol (2014) 0.88
Evaluation of P450 inhibition and induction by artemisinin antimalarials in human liver microsomes and primary human hepatocytes. Drug Metab Dispos (2012) 0.87